<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1.</segment>
<segment id="2" parent="1002" relname="preparation">Introduction</segment>
<segment id="3" parent="1003" relname="preparation">Cancer is a major cause of human death worldwide .</segment>
<segment id="4" parent="1004" relname="span">Most cancer patients receive chemotherapy and radiation therapy ,</segment>
<segment id="5" parent="1005" relname="joint">they are often only partially effective</segment>
<segment id="6" parent="1005" relname="joint">and lead to a variety of serious side effects .</segment>
<segment id="7" parent="1007" relname="span">In recent decades , cancer immunotherapy has been validated</segment>
<segment id="8" parent="1008" relname="span">as stimulating patients ’ own immune systems</segment>
<segment id="9" parent="8" relname="purpose">to eliminate cancers .</segment>
<segment id="10" parent="1011" relname="attribution">Compared to chemotherapy and radiation therapy ,</segment>
<segment id="11" parent="1011" relname="span">cancer immunotherapy can specifically target tumor cells</segment>
<segment id="12" parent="1012" relname="span">by modulating immune cells</segment>
<segment id="13" parent="12" relname="manner">without damage to normal cells .</segment>
<segment id="14" parent="1015" relname="span">A variety of cancer immunotherapies ,</segment>
<segment id="15" parent="14" relname="elaboration">including DC-based cancer vaccines , chimeric antigen receptor-T lymphocyte therapies , immune checkpoint blockade antibody therapies , oncolytic vaccine , and cytokines therapies ,</segment>
<segment id="16" parent="1016" relname="span">have been developed</segment>
<segment id="17" parent="16" relname="purpose">to induce tumor-specific and cytotoxic T lymphocyte immune responses .</segment>
<segment id="18" parent="1018" relname="span">Dendritic cell based therapies have been widely investigated</segment>
<segment id="19" parent="1020" relname="span">because dendritic cells</segment>
<segment id="20" parent="19" relname="elaboration">( DCs ) are thought to be the initiator</segment>
<segment id="21" parent="1019" relname="same_unit">in modulating immunity .</segment>
<segment id="22" parent="1023" relname="span">DCs are known as professional antigen-presenting cells ,</segment>
<segment id="23" parent="1024" relname="span">responsible for swallowing tumor-associated antigens ,</segment>
<segment id="24" parent="1025" relname="joint">presenting them to T lymphocytes ,</segment>
<segment id="25" parent="1025" relname="joint">and inducing antigen-specific immune responses .</segment>
<segment id="26" parent="1026" relname="joint">When DCs mature</segment>
<segment id="27" parent="1027" relname="span">and become activated ,</segment>
<segment id="28" parent="1028" relname="joint">they will swallow the foreign substances</segment>
<segment id="29" parent="1029" relname="span">and subsequently present the antigenic epitopes on major histocompatibility complex</segment>
<segment id="30" parent="29" relname="elaboration">( MHC ) molecules .</segment>
<segment id="31" parent="1031" relname="same_unit">At the same time , DCs up-regulate the maturation receptor ,</segment>
<segment id="32" parent="1032" relname="joint">release potent cytokines ,</segment>
<segment id="33" parent="1033" relname="span">and migrate into lymph nodes</segment>
<segment id="34" parent="33" relname="purpose">to induce systemic immune responses .</segment>
<segment id="35" parent="1034" relname="joint">The standard DC-based vaccine begins with first isolating DCs from the patient .</segment>
<segment id="36" parent="1036" relname="joint">Then , DCs are stimulated with the patient ’s tumor-associated antigen in vitro ,</segment>
<segment id="37" parent="1037" relname="span">and the antigen-stimulated DCs are injected directly back into the patient</segment>
<segment id="38" parent="37" relname="purpose">to induce the activation of T lymphocytes .</segment>
<segment id="39" parent="1039" relname="span">The patient ’s immune system will generate the tumor-specific immune response</segment>
<segment id="40" parent="1040" relname="joint">to destroy cancer cells</segment>
<segment id="41" parent="1040" relname="joint">and prevent cancer recurrence .</segment>
<segment id="42" parent="1041" relname="joint">However , several drawbacks restrict the clinical efficacy of DC therapy .</segment>
<segment id="43" parent="1043" relname="joint">First , only a few DCs actually migrate to the lymph nodes</segment>
<segment id="44" parent="1044" relname="span">and interact with T lymphocytes ,</segment>
<segment id="45" parent="1045" relname="span">with the result of a failure</segment>
<segment id="46" parent="45" relname="purpose">to induce antitumor immune responses .</segment>
<segment id="47" parent="1047" relname="span">Moreover , the in vitro culture cannot generate sufficiently powerful DCs ,</segment>
<segment id="48" parent="47" relname="result">with the result of a weak immune response and limited therapeutic benefit .</segment>
<segment id="49" parent="1049" relname="span">Thus , it is important to establish an in vitro culturing system or an in vivo DC delivery system</segment>
<segment id="50" parent="1050" relname="joint">that can more reliably induce the immune response</segment>
<segment id="51" parent="1050" relname="joint">and more potently deliver antitumor immunity .</segment>
<segment id="52" parent="1053" relname="joint">The lymph nodes are extremely critical in responses to pathogens or danger signals ,</segment>
<segment id="53" parent="1054" relname="span">and their major functions are to filter out deleterious substances by their unique mesh microstructure ,</segment>
<segment id="54" parent="53" relname="purpose">to maintain matured immunocytes ,</segment>
<segment id="55" parent="1052" relname="joint">and to initiate the antigen-specific adaptive immune response .</segment>
<segment id="56" parent="1058" relname="span">The lymph nodes might lose their function</segment>
<segment id="57" parent="1059" relname="joint">because of cancer , obstruction , or infection ;</segment>
<segment id="58" parent="1059" relname="joint">in such cases , surgical resection of lymph nodes is usually indicated .</segment>
<segment id="59" parent="1057" relname="contrast">However , lymph node resection often causes a wide range of other problems such as increased infection , impaired cancer surveillance , and lymphedema .</segment>
<segment id="60" parent="1057" relname="elaboration">Consequently , a promising technique for functional lymph node restoration is urgently needed .</segment>
<segment id="61" parent="1061" relname="span">Decellularization has emerged as a process</segment>
<segment id="62" parent="1063" relname="span">for producing a natural extracellular matrix</segment>
<segment id="63" parent="62" relname="elaboration">( ECM ) ,</segment>
<segment id="64" parent="1063" relname="elaboration">which preserves the intrinsic biological cues and architectural structure of the original tissue .</segment>
<segment id="65" parent="1065" relname="span">It provides a strategy</segment>
<segment id="66" parent="1066" relname="span">by which to fabricate lymph node scaffolds</segment>
<segment id="67" parent="66" relname="elaboration">on which to grow immune cells with immunological function .</segment>
<segment id="68" parent="1069" relname="attribution">Previous studies demonstrated</segment>
<segment id="69" parent="1069" relname="joint">that spleen-derived decellularized ECM or lymph node-associated decellularized ECM can deliver immune cells</segment>
<segment id="70" parent="1070" relname="joint">and promote the organization of lymphoid-like scaffolds ;</segment>
<segment id="71" parent="1070" relname="joint">however , whether these can induce antigen-specific immunity or the antitumor immune response is still unknown .</segment>
<segment id="72" parent="1073" relname="span">The aim of this study was to establish a natural decellularized lymph node scaffold</segment>
<segment id="73" parent="72" relname="elaboration">( dLN ) , with preserved original microstructure and ECM ,</segment>
<segment id="74" parent="1072" relname="joint">and to validate the ability of the dLN to support DC proliferation and maturation in vitro .</segment>
<segment id="75" parent="1074" relname="span">The study also aimed to verify whether a bone marrow dendritic cell</segment>
<segment id="76" parent="75" relname="elaboration">( BMDC)-dLN can activate a specific antitumor immune response in vivo .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="multinuc" parent="4" relname="elaboration"/>
<group id="1006" type="multinuc" parent="1004" relname="elaboration"/>
<group id="1007" type="span" parent="1006" relname="joint"/>
<group id="1008" type="span" parent="7" relname="manner"/>
<group id="1009" type="multinuc" parent="1006" relname="joint"/>
<group id="1010" type="span" parent="1009" relname="joint"/>
<group id="1011" type="span" parent="1010" relname="span"/>
<group id="1012" type="span" parent="11" relname="means"/>
<group id="1013" type="multinuc" parent="1009" relname="joint"/>
<group id="1014" type="multinuc" parent="1013" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="same_unit"/>
<group id="1016" type="span" parent="1014" relname="same_unit"/>
<group id="1017" type="multinuc" parent="1013" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="multinuc" parent="18" relname="cause"/>
<group id="1020" type="span" parent="1019" relname="same_unit"/>
<group id="1021" type="multinuc" parent="1017" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="span"/>
<group id="1024" type="span" parent="22" relname="elaboration"/>
<group id="1025" type="multinuc" parent="23" relname="elaboration"/>
<group id="1026" type="multinuc" parent="1023" relname="circumstance"/>
<group id="1027" type="span" parent="1026" relname="joint"/>
<group id="1028" type="multinuc" parent="27" relname="elaboration"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1021" relname="joint"/>
<group id="1031" type="multinuc" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="same_unit"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="multinuc" parent="1030" relname="joint"/>
<group id="1035" type="multinuc" parent="1034" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="span" parent="1035" relname="joint"/>
<group id="1039" type="span" parent="1041" relname="concession"/>
<group id="1040" type="multinuc" parent="39" relname="purpose"/>
<group id="1041" type="multinuc" parent="1038" relname="span"/>
<group id="1042" type="multinuc" parent="1041" relname="joint"/>
<group id="1043" type="multinuc" parent="1042" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="44" relname="result"/>
<group id="1046" type="multinuc" parent="1042" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="joint"/>
<group id="1048" type="multinuc" parent="1046" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="multinuc" parent="49" relname="elaboration"/>
<group id="1051" type="multinuc" parent="1048" relname="joint"/>
<group id="1052" type="multinuc" parent="1051" relname="joint"/>
<group id="1053" type="multinuc" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1053" relname="joint"/>
<group id="1055" type="multinuc" parent="1051" relname="joint"/>
<group id="1056" type="span" parent="1055" relname="joint"/>
<group id="1057" type="multinuc" parent="1056" relname="span"/>
<group id="1058" type="span" parent="1057" relname="contrast"/>
<group id="1059" type="multinuc" parent="56" relname="cause"/>
<group id="1060" type="multinuc" parent="1055" relname="joint"/>
<group id="1061" type="span" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="61" relname="purpose"/>
<group id="1063" type="span" parent="1062" relname="span"/>
<group id="1064" type="multinuc" parent="1060" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="joint"/>
<group id="1066" type="span" parent="65" relname="elaboration"/>
<group id="1067" type="multinuc" parent="1064" relname="joint"/>
<group id="1068" type="span" parent="1067" relname="joint"/>
<group id="1069" type="multinuc" parent="1068" relname="span"/>
<group id="1070" type="multinuc" parent="1069" relname="joint"/>
<group id="1071" type="multinuc" parent="1067" relname="joint"/>
<group id="1072" type="multinuc" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1072" relname="joint"/>
<group id="1074" type="span" parent="1071" relname="joint"/>
	</body>
</rst>
